Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0OV2F
|
|||
| Drug Name |
212Pb-labelled DOTAMTATE
|
|||
| Drug Type |
Radiopharmaceutical therapy agent
|
|||
| Indication | Neuroendocrine cancer [ICD-11: 2B72.1; ICD-9: 209] | Phase 1 | [1] | |
| Company |
OranoMed/Radiomedix
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Somatostatin receptor (SSTR) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03466216) Phase 1 Study of AlphaMedix in Adult Subjects With SSTR (+) NET. U.S. National Institutes of Health. | |||
| REF 2 | Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.